An Antibody‐CRISPR/Cas Conjugate Platform for Target‐Specific Delivery and Gene Editing in Cancer
Advanced Science · 2024
DOI: 10.1002/advs.202308763 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Seungju Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, 34141, Republic of Korea. Hauptthemen laut MEDLINE: Gene Editing, CRISPR-Cas Systems. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Health and Welfare.
Abstract (Originalsprache)
The CRISPR/Cas system has been introduced as an innovative tool for therapy, however achieving specific delivery to the target has been a major challenge. Here, an antibody‐CRISPR/Cas conjugate platform that enables specific delivery and target gene editing in HER2‐positive cancer is introduced. The CRISPR/Cas system by replacing specific residues of Cas9 with an unnatural amino acid is engineered, that can be complexed with a nanocarrier and bioorthogonally functionalized with a monoclonal antibody targeting HER2. The resultant antibody‐conjugated CRISPR/Cas nanocomplexes can be specifically delivered and induce gene editing in HER2‐positive cancer cells in vitro. It is demonstrated that the in vivo delivery of the antibody‐CRISPR/Cas nanocomplexes can effectively disrupt the plk1 gene in HER2‐positive ovarian cancer, resulting in substantial suppression of tumor growth. The current study presents a useful therapeutic platform for antibody‐mediated delivery of CRISPR/Cas for the treatment of various cancers and genetic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, Korea Advanced Institute of Science and Technology, Daejeon, 34141, Republic of Korea.
- Department of Internal Medicine, Seoul National University Hospital, Seoul, 03080, Republic of Korea.
- Cancer Research Institute, Seoul National University, Seoul, 03080, Republic of Korea.
- College of Pharmacy, Gyeongsang National University, Jinju, 52828, Republic of Korea.
ORCID-Profile: Hyun Jung Chung
Förderung
- National Research Foundation of Korea
- Ministry of Health and Welfare
Zitieren
APA
Yang, S., Im, S. H., Chung, J. Y., Lee, J., Lee, K. H., Kang, Y. K., & Chung, H. J. (2024). An Antibody‐CRISPR/Cas Conjugate Platform for Target‐Specific Delivery and Gene Editing in Cancer. Advanced Science. https://doi.org/10.1002/advs.202308763
Vancouver
Yang S, Im SH, Chung JY, Lee J, Lee KH, Kang YK, et al. An Antibody‐CRISPR/Cas Conjugate Platform for Target‐Specific Delivery and Gene Editing in Cancer. Advanced Science. 2024. doi:10.1002/advs.202308763
BibTeX
@article{Yang2024,
author = {Yang, Seungju and Im, San Hae and Chung, Ju Yeon and Lee, Juhee and Lee, Kyung-Hun and Kang, Yoo Kyung and Chung, Hyun Jung},
title = {An Antibody‐CRISPR/Cas Conjugate Platform for Target‐Specific Delivery and Gene Editing in Cancer},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202308763}
}
EUVIMED